aTyr Pharma (ATYR) Set to Post Earnings on Thursday

aTyr Pharma (NASDAQ:ATYR) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.11) per share and revenue of $2.50 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. On average, analysts expect aTyr Pharma to post ($0.44) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

aTyr Pharma Stock Performance

Shares of aTyr Pharma stock opened at $0.13 on Thursday. aTyr Pharma has a one year low of $0.10 and a one year high of $1.11. The company has a market cap of $12.59 million, a P/E ratio of -0.21 and a beta of 0.91. The firm has a fifty day moving average of $0.35 and a two-hundred day moving average of $0.61.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ATYR shares. Wall Street Zen upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings downgraded shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, aTyr Pharma currently has a consensus rating of “Moderate Buy”.

aTyr Pharma Company Profile

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.